FDA Commissioner Dr. Marty Makary on Accelerating Biosimilar Drug Approvals to Lower Healthcare Costs

Tackling Drug Price Inflation

• 💡 The fastest growing area of healthcare spending in the U.S. is drug price inflation, particularly for expensive biologics.
• 🎯 Biologics, complex molecules derived from cell lines, represent 5% of medications but over half of drug costs.
• 🔑 The goal is to increase the availability of biosimilar generic drugs to make these essential medications more affordable.

Streamlining Biosimilar Approvals

• 🚀 The FDA is reducing the required studies for biosimilar approval from extensive comparative studies to a smaller set of PK studies.
• ⏱️ This change aims to cut the development time for biosimilars from 5-8 years down to 2.5 to 5 years.
• 📈 The FDA aims to have hundreds of biosimilars approved, compared to the current 76 approved in the last decade.

Addressing Industry Pushback and Innovation

• ⚠️ While pharmaceutical companies may resist changes that reduce red tape, there are still significant incentives for innovation.
• ⏳ Market exclusivity for biologics remains long (average 12 years), ensuring continued investment in new drug development.
• 📉 The arrival of multiple biosimilars for a drug like Humira led to significant price reductions, demonstrating the impact of competition.

Proactive FDA Approach to Drug Development

• ✨ A new FDA program issues priority review vouchers to expedite decisions, aiming for outcomes in weeks instead of a year.
• 🤝 The FDA is shifting from a passive role to a proactive one, partnering with companies to accelerate the development of cures and treatments.
• 🔬 The agency is actively seeking out groundbreaking therapies and working to cut red tape and idle time for promising treatments.

Expanding Access to Novel Therapies

• 🩺 The FDA is advocating for programs like the pediatric priority review voucher to further reduce review times to six months.
• 💡 The agency is experimenting with radically new approaches, like the priority review voucher, to challenge the lengthy 10-12 year timeline for new drugs to reach the market.
• 🌟 This proactive stance is driven by the desire to offer life-changing and curative treatments to patients sooner.